EGFR and non-small cell lung carcinoma: As shown in Figure 5B, pooled HR was 1.33 for DFS (95% CI 0.97-1.84, p=0.076) based on six studies [10, 24, 25, 32, 43, 47] conducted in stage I-IIIa resected NSCLC comparing KRAS mutant tumors with KRAS and EGFR wild-type tumors, exhibiting an insignificant trend towards increased hazard for disease recurrence after tumor resection for KRAS mutant patients.